@article{oai:u-ryukyu.repo.nii.ac.jp:02016867,
 author = {渡邉, 孝 and 菅原, 健一 and 長嶺, 英樹 and 石内, 勝吾 and Watanabe, Takashi and Sugawara, Kenichi and Nagamine, Hideki and Ishiuchi, Shogo},
 issue = {1-3},
 journal = {琉球医学会誌 = Ryukyu Medical Journal},
 note = {Glioblastoma multiforme is the most malignant tumor occurring in the central nervous system and is incurable by current therapeutic strategies. The serine/threoninespecific protein kinase, Akt, is frequently dysregulated and affects cell survival and proliferation in many human cancers, including glioblastoma. Inhibition of Akt phosphorylation has demonstrated therapeutic potential against glioblastoma. Many inhibitors of the PI3K-Akt signaling pathway and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)-Akt signaling pathway are in clinical use and have demonstrated preliminary activity against various tumor types. This review describes the limitations of therapy against glioblastoma targeting single dysregulated pathways because of the presence of diverse signaling pathways that regulate the coactivation of multiple tyrosine kinases in most malignant gliomas, and the requirement for combined approaches targeting the multiple Akt-mediated signaling pathways based on the findings of clinical trials and earlier investigations., 論文},
 pages = {1--7},
 title = {[総説]神経膠芽腫に対するAkt を標的とした分子標的療法},
 volume = {33}
}